Description
This blend pairs CJC-1295 without DAC (Modified GRF 1-29), a short-acting analogue of growth hormone releasing hormone, with ipamorelin, a selective pentapeptide agonist of the ghrelin receptor GHS-R1a.
GHRH-receptor and ghrelin-receptor agonists act through distinct signalling pathways on pituitary somatotrophs, and animal research has long examined how co-activation of the two receptors affects the amplitude of growth hormone pulses compared with either agent alone. A pre-combined vial is convenient for experiments that study this synergy under consistent conditions. Each vial contains 5 mg of each peptide. Researchers should account for both components when designing controls, ideally including single-peptide arms.
Keep vials sealed and cold until use.
Supplied for research purposes only and must not be used as a drug, food additive or cosmetic. Not for human or veterinary use.
Supplied as a 10-vial kit of lyophilised powder. Dispatched in 1–2 business days.




